For any product with European and UK market ambitions in 2026, the HTA submission landscape has fundamentally changed. NICE requires a QALY-based cost-effectiveness model. G-BA requires a head-to-head added benefit assessment against its independently defined comparator. HAS requires clinical benefit and clinical improvement ratings that directly determine the reimbursement rate. Each body operates on a different evidence standard, uses a different comparator definition, and has a different submission timeline. And with the EU JCA in force from January 2025, the complexity compounds further: the JCA assessment runs in parallel with EMA review, with only 90 days between scope communication and dossier submission deadline.[2]
Managing three parallel HTA submissions from a single evidence base, without producing factual inconsistencies that an astute reviewer can identify and challenge, is the defining multi-HTA challenge for HEOR teams in 2026. Pienomial's Knolens platform provides the market access analytics platform and enterprise intelligence platform infrastructure that enables HEOR teams to build a shared evidence layer, generate body-specific dossier content with full consistency, and satisfy the growing audit requirements of NICE, G-BA, and HAS within a single governed workflow.[9]
1. NICE, G-BA, and HAS: A Precise Evidence Standard Comparison
The three bodies assess the same clinical evidence through fundamentally different frameworks. Understanding the specific differences is the starting point for a multi-HTA evidence strategy.[1]
NICE (UK): QALY-based cost-effectiveness analysis. The standard ICER approval range is £20,000 to £30,000 per QALY gained, with evidence-based flexibility for end-of-life conditions, highly specialised technologies, and products with significant innovation. Probabilistic sensitivity analysis is required to characterise decision uncertainty. EQ-5D is the preferred utility measurement instrument. NICE increasingly requests real-world evidence for products with limited trial follow-up or narrow trial populations.[1]
G-BA (Germany): Added benefit assessment under the AMNOG process. The appropriate comparator therapy, the zweckmäßige Vergleichstherapie or ZVT, is defined by the G-BA independently before the manufacturer's trial, not by the manufacturer or the trial design. Only patient-relevant endpoints are accepted: mortality, morbidity, quality of life, and adverse events. QALY methodology is not used. The dossier must be submitted on day one of EU market launch, making evidence readiness at the time of EMA approval a non-negotiable operational requirement.
HAS (France): Clinical benefit rating (SMR: Service Médical Rendu) and clinical improvement rating (ASMR: Amélioration du Service Médical Rendu). The SMR determines the reimbursement rate directly: major or important SMR receives 65% reimbursement, moderate SMR receives 30%, and weak SMR receives 15%. [3] Research on 146 HAS assessments from 2014 to 2020 found that ASMR ratings are positively associated with disease severity, QALY gain, and validation of the cost-utility ratio. [4] HAS submissions are due within 12 months of EU launch, providing slightly more preparation time than G-BA's day-zero deadline.
2. The Comparator Misalignment Problem
The most common and most consequential multi-HTA failure mode is comparator misalignment: different HTA bodies defining different appropriate comparators for the same product.[7]
In a typical oncology scenario, G-BA may define the ZVT for a second-line NSCLC product as docetaxel monotherapy, based on the German guideline standard of care at the time of scope definition. NICE may position the same product against an atezolizumab-based combination that has become the standard of care in England. HAS may require comparison against the most recently assessed reference therapy for the indication in France. Three bodies, three comparators, all of them potentially different from the trial's active comparator.
If the Phase III trial was designed against docetaxel only, NICE and HAS will require indirect treatment comparisons against their preferred alternatives. The ITC may not be feasible given the available trial network. G-BA may accept the docetaxel comparison, but the resulting ZVT-relevant data may not be the data that NICE needs. The consequence: submissions that satisfy G-BA's comparator requirement fail to satisfy NICE's, and a product that achieves a positive G-BA outcome may receive restricted or conditional reimbursement from NICE for inadequate comparator evidence.
AI prevents this at the planning stage. KnolAI analyses G-BA ZVT decisions, NICE appraisal comparators, and HAS reference therapy assessments for analogous products in the same indication and mechanism class, generating a multi-HTA comparator map before Phase III protocol lock. This map enables clinical development teams to design trials that maximise comparator relevance across all three bodies, rather than optimising for one body and discovering the gap for the others at submission.[9]
3. Building the Shared Evidence Layer for Multi-HTA
The foundational principle of multi-HTA evidence architecture is that three submissions should draw from one governed evidence layer, with body-specific contextualisation applied at the output layer rather than by generating separate evidence for each body.[1]
Knolens operates as a market access analytics platform that ingests all relevant clinical data, published evidence, HTA precedent decisions, and real-world evidence into a structured, continuously updated knowledge base. Evidence modules are tagged by HTA body applicability. A PFS hazard ratio result from a pivotal trial is stored once with its source. For NICE, it is retrieved and framed within a cost-effectiveness modelling context with survival extrapolation parameters. For G-BA, it is retrieved and assessed against IQWiG surrogate validation criteria for patient relevance. For HAS, it is retrieved and contextualised within the SMR and ASMR comparative effectiveness framework.[9]
The consistency mechanism is architectural. Because all three submissions draw from the same evidence modules, the factual claims are identical across submissions. A reviewer with access to more than one submission will find the same clinical numbers, attributed to the same sources, framed in the methodological language each body expects. The cross-submission consistency check in KnolComposer flags any factual inconsistency before submission, preventing the reviewer trap where identical clinical data is presented with different quantitative values across submissions.
Indirect treatment comparisons are required in the majority of multi-HTA submissions, because each body independently defines appropriate comparators and those definitions rarely align perfectly with the trial's active comparator. Methodology requirements differ across bodies.[5]
NICE follows NICE DSU Technical Support Document guidance, preferring Bayesian network meta-analysis with probabilistic sensitivity analysis and full uncertainty characterisation. G-BA accepts adjusted indirect comparisons where NMA is not feasible, with strict heterogeneity documentation and relative treatment effects expressed as hazard ratios with 95% confidence intervals. HAS follows French HAS methodology guidance, accepts NMA with sensitivity analyses, and requires explicit discussion of heterogeneity and the treatment network.
KnolAI structures the multi-HTA ITC by identifying all relevant trials in the treatment network from the knowledge layer, mapping common comparators, quantifying heterogeneity signals, and assessing the feasibility of each body's required comparison. The output is a single structured ITC dataset with traceable source attribution for every data point. KnolComposer generates the ITC methodology section in the format required by each body from the same dataset, with appropriate statistical presentation and language adaptation. The underlying analysis is identical. The presentation is body-specific.[9]
5. The G-BA Day-Zero Constraint and Submission Timeline Management
The G-BA AMNOG timeline is the most time-pressured constraint in multi-HTA submission management. The dossier must be submitted on day one of EU market launch. All evidence, including head-to-head trial data, ITC analyses, subgroup analyses, and patient-relevant endpoint documentation, must be submission-ready at the time of EMA approval, not in the weeks or months following it.[1]
This constraint transforms multi-HTA evidence preparation from a sequential project into a parallel programme. Traditional workflow: G-BA first, then NICE, then HAS, each building from the shared evidence base with a dedicated team. The timeline is managed by giving G-BA highest priority. AI-enabled workflow: all three body-specific dossier sections are generated simultaneously from the shared knowledge layer. The resource requirement shifts from three sequential teams to a core evidence team supported by KnolAI and KnolComposer, with body-specific expert review focused on strategic framing and quality validation rather than evidence compilation.
NICE submissions typically follow 90 days after UK regulatory approval, providing more preparation time. HAS accepts submissions within 12 months of EU launch. The JCA submission, required simultaneously with the EMA application, now precedes all three national submissions, making the JCA the first-mover constraint that shapes the evidence architecture for the entire multi-HTA programme.[2]
6. AI Use in HTA Submissions: What Transparency Is Now Required
NICE published its formal position statement on AI in evidence generation in August 2024, requiring transparent reporting using PALISADE and TRIPOD+AI checklists when AI tools are used in evidence synthesis or dossier preparation. [5] At the 2025 NICE conference, the evidence from AI-assisted SLRs was cited as achieving a 95% reduction in staff requirement and a 50% reduction in time, with NICE confirming that its 2024 position statement has been licensed by other HTA bodies for their own use.[6]
For multi-HTA submissions, the transparency requirement applies across all three bodies. The documentation standard that NICE requires for AI use, including declaration of tools, methodology description, and human oversight evidence, is now the minimum standard for any multi-HTA submission that uses AI in evidence generation. For HEOR teams using Knolens to generate multi-HTA evidence, this documentation is generated automatically as part of the audit trail that KnolAI maintains for all evidence synthesis actions.[9]
7. Cross-Submission Consistency: The Reviewer Trap
A NICE reviewer who has access to the published G-BA assessment document, which is publicly available in German within approximately three months of submission, will compare clinical claims across submissions. The G-BA assessment document explicitly quotes from the manufacturer's dossier. If the same clinical endpoint is characterised differently in the NICE submission than in the G-BA dossier, or if different numerical values appear for the same result, the NICE reviewer has grounds to issue a formal clarification request that delays the appraisal.[7]
The cross-submission consistency check in KnolComposer operates before any submission is finalised. It compares factual clinical claims across all body-specific dossier versions: endpoint definitions, hazard ratio values, confidence intervals, patient population descriptions, and comparator characterisations. Any factual inconsistency is flagged for human review and resolution before the dossier is released for submission. Body-specific language adaptation, QALY framing for NICE, Zusatznutzen framing for G-BA, and benefit rating framing for HAS, is permitted and expected. Factual divergence is identified and blocked.
8. Responding to Simultaneous HTA Reviewer Queries
HTA bodies issue clarification requests during their assessment process. For products under simultaneous multi-HTA review, these queries may arrive in the same week. NICE issues a formal list of clarification questions approximately four weeks after submission. G-BA requests hearing attendance within twelve weeks. HAS may issue questions at any point during its assessment. A HEOR team managing all three simultaneously may face concurrent queries on different aspects of the same evidence base from three different bodies with different methodological expectations.[8]
The shared evidence layer is the response infrastructure. When a NICE query arrives about survival extrapolation methodology, the relevant evidence module is retrieved from the knowledge layer. KnolComposer generates the response in NICE's required format with full source attribution. When a G-BA question arrives simultaneously about ZVT comparator relevance, the response is generated from the same knowledge layer with G-BA framing. The cross-submission consistency check confirms that the responses to both bodies are factually aligned.
The speed advantage is critical. HTA bodies typically allow four to six weeks for clarification responses. A HEOR team that must reconstruct the evidence basis for a specific claim from original source documents under time pressure produces a weaker response than a team that retrieves the relevant evidence module from a governed knowledge layer and generates a traceable response in hours.[9]
9. How Fast Can Your Team Go Live with Multi-HTA Submissions on Knolens?"
Building a multi-HTA evidence capability does not require months of infrastructure work before your first dossier section is generated. Knolens ships with pre-built evidence templates for NICE, G-BA, and HAS, pre-loaded HTA precedent data across all three bodies, and ready-to-run ITC and evidence synthesis pipelines configured for multi-body parallel output. The platform is already architected for simultaneous multi-HTA submission. You are configuring it to your indication, not constructing it from scratch.
Most HEOR teams are generating their first body-specific dossier sections from a shared evidence layer within six weeks of onboarding. Here is what that looks like.
Sprint 1, Weeks 1 to 2, Multi-HTA evidence landscape live: Knolens is connected to your indication and target submission scope. KnolAI runs the first automated multi-HTA landscape analysis, identifying the comparator map for NICE, G-BA, and HAS from analogous precedent submissions, endpoint patient-relevance history for each body, and ITC methodology expectations. Your team receives the initial multi-HTA evidence requirements brief covering all three bodies simultaneously. No manual precedent research required. [9]
Sprint 2, Weeks 3 to 4, Shared evidence layer built and tagged: Clinical trial data, SLR outputs, ITC analysis, and available RWE are ingested into the shared knowledge layer with full source attribution. Each evidence module is tagged by HTA body applicability automatically. Body-specific framing templates for NICE, G-BA, and HAS are activated. The cross-submission consistency check framework is configured so any factual divergence across body-specific outputs is flagged before generation completes.
Sprint 3, Weeks 5 to 6, First parallel dossier sections generated: KnolComposer generates NICE, G-BA, and HAS dossier sections simultaneously from the shared evidence layer. The NICE section uses QALY framing and probabilistic sensitivity analysis language. The G-BA section uses patient-relevant endpoint framing with ZVT comparator context. The HAS section uses SMR and ASMR comparative effectiveness framing. All three draw from the same clinical numbers, attributed to the same sources. The cross-submission consistency check runs automatically before any section is released for expert review. Body-specific expert reviewers focus on strategic framing validation, not on rebuilding the evidence base. [7]
From Sprint 3 onward, Knolens maintains the shared evidence layer continuously. When the G-BA day-zero submission deadline arrives, the dossier is ready because evidence preparation ran in parallel with trial execution, not after it. When simultaneous HTA reviewer queries arrive from different bodies in the same week, responses are generated from the same knowledge layer in hours. When new evidence becomes available post-submission, evidence modules update and relevant dossier sections refresh without requiring a full evidence rebuild. [2]
Conclusion
Multi-HTA market access in 2026 is not a project management challenge. It is an evidence architecture challenge. NICE, G-BA, and HAS each assess the same product through different methodological frameworks, with different comparator requirements, different evidence standards, and misaligned submission timelines. The organisations achieving the best multi-HTA outcomes are those treating the three submissions as a coordinated programme drawing from one governed evidence base, not three separate projects.[2]
Pienomial's Knolens platform, as the market access analytics platform and enterprise intelligence platform built for this challenge, enables HEOR teams to build the shared evidence architecture, generate body-specific dossier content with full consistency, and satisfy the growing transparency requirements of NICE, G-BA, and HAS. The teams deploying this infrastructure before their next submission cycle will achieve faster, more consistent, and more defensible multi-HTA market access outcomes. [9] CTA: Book a Multi-HTA Market Access Strategy Consultation with Pienomial's Evidence Team.
